Germany’s Merck KGaA (MKGAY), which had confirmed in February it was in advanced talks to buy SpringWorks Therapeutics (SWTX), is nearing a roughly $3.5B deal for the U.S. biopharmaceutical company that specializes in rare diseases and cancer, people familiar with the matter told The Wall Street Journal’s Ben Dummett and Lauren Thomas. The two parties have agreed on a price close to $47 per share, and a deal could be completed as soon as Monday, the report added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks EU approval would enhance strategic value, says Evercore
- Positive opinion for Ogsiveo would de-risk SpringWorks deal, says Barclays
- SpringWorks Therapeutics price target lowered to $84 from $87 at BofA
- Merck KGaA says ‘no certainty’ SpringWorks deal will be signed
- SpringWorks cancelled from conference this week, says Barclays